甲状腺乳头状癌中BIM基因表达及其与BRAF^V600E突变的相关性研究  

Expression of BIM gene in papillary thyroid carcinoma and its association with the BRAF^V600E mutation

作　　者：廖登辉[1] 王婷[1] 杨在亮[1] 甘霖[1] 曾真[1] 王亚冬[1] 闵捷[1] 吕钢[1] 

机构地区：[1]重庆市中医院乳腺甲状腺科,400021

出　　处：《中华内分泌代谢杂志》2015年第7期604-605,共2页Chinese Journal of Endocrinology and Metabolism

基　　金：重庆市卫生计委医学科研项目（20143005）

摘　　要：通过检测甲状腺乳头状癌（PTC）中BRAF^V600E突变与促凋亡基因BIM表达的情况，探讨两者的关系以及它们与甲状腺乳头状癌临床病理特征的关系。应用突变等位基因特异性扩增（MASA—PCR）和直接测序法，qPCR技术分别检测61例PTC组织及与其配对正常甲状腺组织中BRAF^V600E突变和BIM基因表达情况，分析BRAF^V600E突变与BIM基因表达的相关性及其与甲状腺乳头状癌临床病理特征的关系。结果提示PTC中BRAF^V600E突变率为54．1％，首次报道含有BRAF^V600E突变的PTC组织中BIM基因的表达水平比野生型和正常甲状腺组织中低，且BRAF^V600E突变与更高的临床TNM（III／IV）分期有关（P〈0．05），而BIM基因的低表达与肿瘤大小及更高的TNM临床分期相关（P〈0．05）。本研究有助于进一步了解PTC的发病机制，为临床诊断和治疗PTC提供了新的线索。To study the link between BRAF^V600E status and the expression of BIM gene in papillary thyroid carcinoma （ PTC ） tissues and to analyze the association of these factors with clinicopathological characteristics. BRAF^V600E status was determined by MASA-PCR, and qPCR was applied to detect the expression of BIM gene. Finally, the associations of these factors with clinicopathological characteristics were analysed. The rate of mutant BRAF^V600E in PTC was 54. 1%, and the expression of BIM gene was lowered in BRAF^V600E positive PTC tissues. Additionally, there was significant association （P 〈 0.05 ） between BRAF^V600E positiveness and raised TNM Staging （ III/IV ）, and lowered BIM expression was significantly associated （ P〈0.05 ） with the tumor size and raised TNM Staging（ III/IV ）. These findings may help us to know more about the mechanism of PTC and to develop new diagnostic biomarkers or prognostic indicators of PTC.

关 键 词：甲状腺乳头状癌 BRAF^V600E BIM基因 

分 类 号：R736.1[医药卫生—肿瘤]